Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Three patients died in Novartis trials of its CD19-directed CAR-T treatment following a dangerous immune system response, and a similar therapy from Bristol Myers Squibb has also been put on hold to review safety issues ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.